[Skip to Navigation]
JAMA Cardiology Clinical Guidelines Synopsis
April 17, 2019

2018 American Heart Association/American College of Cardiology/Multisociety Guideline on the Management of Blood Cholesterol–Secondary Prevention

Author Affiliations
  • 1Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas
  • 2Northwestern University Feinberg School of Medicine, Chicago, Illinois
JAMA Cardiol. 2019;4(6):589-591. doi:10.1001/jamacardio.2019.0911

Atherosclerotic cardiovascular disease (ASCVD) is the most common cause of death in the United States.1 Most deaths from ASCVD occur in patients with preexisting ASCVD. Secondary prevention trials in patients with established ASCVD demonstrate that low-density lipoprotein cholesterol (LDL-C)–lowering therapy with statins reduces recurrent cardiovascular events. Recently, new nonstatin drugs, notably ezetimibe and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, have been introduced as statin add-on drugs for LDL-C lowering. This article reviews evidence-based strategies for reducing LDL-C in secondary prevention.

Add or change institution